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Abstract	
The	chemokine	receptor	CCR4	was	highly	expressed	in	human	renal	cell	carcinoma	(RCC)	
biopsies	and	there	were	abnormal	levels	of	CCR4	ligands	in	RCC	patient	plasma.	An	anti-
CCR4	antagonistic	antibody	had	novel	anti-tumor	activity	in	the	mouse	RCC	RENCA	
model.	Inhibition	of	CCR4	did	not	reduce	the	proportion	of	infiltrating	leukocytes	in	the	
tumor	microenvironment	but	altered	the	phenotype	of	myeloid	cells,	increased	NK	cells	
and	Th1	cytokine	levels,	as	well	as	reducing	the	immature	myeloid	cell	infiltrate,	and	
blood	chemokine	levels.	Although	prominent	changes	were	seen	in	the	myeloid	
compartment,	the	anti-CCR4	antibody	had	no	effects	on	RENCA	tumors	grown	in	T-cell	
deficient	mice,	and	anti-tumor	activity	was	abrogated	by	treatment	with	an	anti-Class	II	
MHC	antibody.	We	conclude	the	action	of	the	anti-CCR4	antibody	required	the	adaptive	
immune	system	and	was	dependent	on	CD4+	T	cells.	Moreover,	when	Th1-polarised	
normal	CD4+	T	cells	were	exposed	to	the	CCR4	ligand	CCL17	production	of	IFNγ	was	
reduced	suggesting	that	CCR4	may	be	more	widely	involved	in	Th1/Th2	regulation.	The	
anti-CCR4	antibody,	alone,	or	in	combination	with	other	immune	modulators,	may	be	of	
interest	in	human	solid	cancers	with	high	levels	of	CCR4-expressing	tumor-infiltrating	
leukocytes	and	abnormal	plasma	CCR4	ligand	levels.	
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Introduction		
Tumor	microenvironments	possess	complex	chemokine	networks	that	contribute	to	the	
extent	and	phenotype	of	the	host	infiltrate	(1-3).	In	addition,	malignant	cells	may	gain	
functional	chemokine	receptors,	often	as	a	consequence	of	oncogenic	mutations,	
allowing	them	to	respond	to	distant	chemokine	gradients	during	metastatic	spread	(4,	
5).		
The	chemokine	receptor	CCR4	is	expressed	on	circulating	and	tissue-resident	T	cells,	
being	predominantly	associated	with	a	Th2	phenotype	(6-8)	as	well	as	on	other	T	helper	
cells	(9).	CCR4	is	also	highly	expressed	on	circulating	Tregulatory	cells,	Tregs,	and	on	
Tregs	recruited	at	tumor	sites	in	ovarian	cancer	(10)	and	in	glioblastoma	(11).	In	ovarian	
cancer,	CCL22	is	found	both	in	the	tumor	tissue	and	in	macrophages	isolated	from	
ascitic	fluid	(9).	In	hepatocellular	carcinoma,	malignant	cell-produced	CCL22	recruited	
CCR4+	Tregs	that	facilitated	immune	escape	of	malignant	cells	(12).	Similarly,	in	breast	
cancer,	CCR4+	Tregs,	recruited	by	CCL22	in	the	tumor	microenvironment,	are	predictive	
for	a	worse	prognosis	(13).	A	second	breast	cancer	study	found	reduced	overall	survival	
and	high	CCR4	expression	in	tumor	biopsies	(14).	Finally,	in	a	cohort	of	753	patients	with	
gastric	adenocarcinoma,	positive	staining	for	CCR4	was	also	associated	with	a	poorer	
prognosis	(15).	
CCR4	also	plays	a	role	in	haematological	malignancies	and	there	are	now	clinical	trials	of	
an	anti-CCR4	antibody,	mogamulizumab,	which	has	enhanced	ADCC	(antibody-
dependent	cell-mediated	cytotoxicity)	activity.	Mogamulizumab	is	approved	in	Japan	for	
the	treatment	of	relapsed	Adult	T	cell	leukemia	(ATL)(16)	and	has	also	been	tested	in	
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patients	with	relapsed	peripheral-T	cell	lymphoma	(PTLC),	and	cutaneous	T-cell	
lymphoma	(CTLC)	(17).	The	treatment	is	indicated	for	patients	with	CCR4-positive	
leukemia	cells,	but	might	also	act	by	reducing	the	number	of	Tregs	in	cancer	patients	
(18).		
In	this	paper	we	have	investigated	CCR4	as	a	target	in	renal	cell	carcinoma,	RCC,	using	
patient	samples	and	an	orthotopic	mouse	RCC	model.	We	have	found	abnormal	levels	of	
CCR4	and	its	ligands	in	human	RCC	biopsies	and	plasma	samples.	In	pre-clinical	
experiments	we	found	that	Affi-5,	a	fully	human	anti-CCR4	antibody	with	antagonistic	
activity,	described	in	(19),	has	a	novel	anti-tumor	activity	in	a	renal	cancer	model.	
Inhibition	of	CCR4	did	not	reduce	the	proportion	of	CCR4-positive	infiltrating	leukocytes	
in	the	tumor	microenvironment	but	altered	the	phenotype	of	the	immune	infiltrate,	
affecting	in	particular	the	phenotype	of	myeloid	cells,	and	increasing	the	number	of	
infiltrating	NK	cells.	These	effects	were	dependent	on	the	adaptive	immune	system	and	
required	functioning	CD4+	T	cells.	The	antibody	also	altered	the	phenotype	of	tumor-
associated	macrophages	in	the	B16	melanoma	model.	Inhibition	of	CCR4,	alone,	or	in	
combination	with	other	immune	modulators,	may	be	a	valuable	therapeutic	approach	in	
human	cancers	with	high	levels	of	CCR4	in	the	tumor	microenvironment	and	abnormal	
plasma	CCR4	ligand	levels.		
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Results	
CCR4	and	its	ligands	in	human	renal	cell	carcinoma	
This	study	was	initially	prompted	by	finding	abundant	CCR4	mRNA	in	biopsies	from	renal	
cancers	as	compared	to	normal	kidney	(Figure	1A).	CCR4	protein	was	also	detected	by	
immunohistochemistry,	IHC,	on	malignant	cells	and	leukocytes	in	a	tissue	microarray,	
TMA,	constructed	from	57	advanced	renal	cell	carcinoma,	RCC,	patient	biopsies	(Figure	
1B,	Supplementary	Figure	1A).	Of	the	173	cores	in	the	TMA,	157	showed	positive	CCR4	
staining.	75%	of	the	biopsies	were	classified	as	clear	cell	with	others	classified	as	
papillary	RCC.	There	was	a	significant	positive	correlation	between	CCR4	positivity	and	
the	extensive	T	cell	(CD3+)	or	macrophage	(CD68+)	infiltrates	in	the	tumor	cores	
(Supplementary	Figure	1B-D),	suggesting	that	CCR4	may	be	important	in	the	trafficking	
of	tumor-associated	leukocytes.	
The	CCR4	ligands	CCL22	(MDC)	and	CCL17	(TARC)	were	also	expressed	in	the	RCC	tumors	
(Figure	1B,	Supplementary	Figure	1A).	CCR4	was	weakly	expressed	in	normal	kidney	but	
the	ligands	could	be	detected	in	normal	kidney	tubules	(Supplementary	Figure	1A).		
We	next	compared	plasma	concentrations	of	CCL17	and	CCL22	from	patients	with	
advanced	RCC	with	age-matched	controls	using	the	MesoScale	Discovery	
electrochemiluminescence	system.	The	concentration	of	CCL17	in	plasma	was	
significantly	higher	in	patients;	however,	the	concentration	of	CCL22	was	significantly	
lower	in	the	patients	compared	to	controls	(Figure	1C,	D).	The	CCL17:	CCL22	ratio	was	
also	significantly	different	between	the	two	groups	and	four-fold	higher	in	patients	
compared	to	controls	(Figure	1E).	Moreover,	a	high	CCL17:	CCL22	ratio	correlated	with	
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lower	progression-free	and	overall	survival	rates	(Figure	1F,	G)	but	this	association	was	
not	seen	if	the	individual	chemokines	were	examined	(Supplementary	Figure	1E,	F)	
suggesting	that	activity	of	both	chemokines	is	important	in	RCC	biology.	In	our	cohort,	
CCR4	expression,	as	determined	by	IHC	on	the	TMAs,	was	not	predictive	of	clinical	
outcome	(not	shown).	
	
Renal	cancer	cell	lines	have	functional	CCR4	receptors	
As	we	had	detected	CCR4	and	its	ligands	in	malignant	cells	in	tumor	biopsies,	we	next	
studied	RCC	cancer	cell	lines.	RCC	cell	lines	786-O	and	A498	(human)	and	RENCA	
(murine)	expressed	cell	surface	CCR4	as	determined	by	flow	cytometry.	The	human	cell	
lines	had	detectable	intracellular	CCL17	and	CCL22	(Supplementary	Figure	2)	and	these	
chemokines	were	also	present	in	the	tissue	culture	medium	during	three	days	
incubation	(CCL17	300	pg/106	cells,	CCL22	2	ng/106	cells).	RENCA	cells	also	secreted	
CCL17	(200	pg/106	cells)	and	CCL22	(10	pg/106	cells)	in	the	medium	during	three	days	
incubation.		
Both	CCR4	ligands	stimulated	migration	of	the	human	cell	line	786-O	(Supplementary	
Figure	3A,	B).	Similar	data	were	obtained	for	A498	(data	not	shown)	and	murine	RENCA	
cells	(Supplementary	Figure	3A,	B)	with	characteristic	bell-shaped	concentration-
response	curves	typical	of	chemokine-mediated	migration,	implicating	that	the	receptor	
can	be	functional	on	malignant	cells.	shRNA	to	CCR4	abolished	CCR4	staining	in	the	RCC	
cells	as	well	as	their	migration	to	CCL17	(Supplementary	Figure	3C,	D).	In	addition,	a	fully	
human	anti-CCR4	antagonistic	antibody,	Affi-5	(19),	abrogated	the	migration	of	786-O	
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cells	to	CCL17,	further	confirming	that	the	CCR4	receptor	is	functional	in	the	tumor	cells	
(Supplementary	Figure	3E).	
	
Anti-tumor	activity	of	an	anti-CCR4	antibody	
Taken	together,	the	above	data	and	the	published	literature	suggest	that	CCR4	is	a	
therapeutic	target	of	interest	in	human	solid	cancers,	especially	as	it	is	expressed	by	
both	malignant	cells	and	tumor-infiltrating	leukocytes.	We	therefore	conducted	pre-
clinical	experiments	using	the	Affi-5	antagonistic	antibody	to	CCR4	in	the	RENCA	mouse	
RCC	model.	Affi-5	inhibited	migration	of	RENCA	cells	to	murine	CCL17	and	CCL22	
showing	that	the	antibody	was	antagonistic	to	murine	CCR4	as	well	as	human	CCR4	
(Figure	2A,	Supplementary	Figure	3F).	Affi-5	did	not	influence	the	growth	or	viability	of	
either	human	or	murine	RCC	cells	in	normal	or	low	serum	or	their	release	of	CCR4	
ligands	(data	not	shown).		
RENCA	cells	labelled	with	luciferase	were	grown	orthotopically	in	their	syngeneic	hosts,	
wild-type	Balb/c	mice,	by	injection	into	the	renal	capsule	of	the	left	kidney.	Mice	
reached	humane	endpoint	during	the	course	of	tumor	growth	between	17-21	days	post	
implantation.	Anti-CCR4	antibody	treatment	significantly	inhibited	tumor	burden	as	
measured	by	tumor	weight	and	bioluminescence	as	compared	to	treatment	with	an	
isotype	control	antibody	(Figure	2B,C).	Figure	2B	shows	the	mean	tumor	weights	at	end	
point	from	six	independent	experiments	with	20	mg/kg	Affi-5	versus	an	isotype	control,	
while	Figure	2C	shows	a	typical	experiment	using	bioluminescence	as	a	measure	of	
tumor	growth.	10	mg/kg	Affi-5	also	had	significant	anti-tumor	activity	(p=0.0003)	(six	
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experiments,	C	n=39,	T	n=42,	p=0.0003,	Figure	2D).		There	was	a	significant	reduction	in	
the	serum	concentration	of	the	CCR4	ligand	CCL17	in	treated	mice	(Figure	2E).	In	
contrast,	serum	concentration	of	CCL22	was	low	and	did	not	change	following	
treatment	(Figure	2F).	Analysis	of	CCL17	and	CCL22	expression	in	tumor	lysates	showed	
that,	adjusted	for	tumor	size,	CCL17	levels	are	stable	while	CCL22	levels	are	higher	in	
anti-CCR4	treated	tumors	(not	shown),	suggesting	that	the	decrease	in	CCL17	circulating	
levels	might	reflect	a	reduction	in	tumor	size.	
	
Actions	of	the	anti-CCR4	antibody	on	tumor-associated	macrophages	
We	considered	that	from	the	data	presented	previously,	as	well	as	from	the	published	
literature,	the	mechanism	of	anti-CCR4	inhibition	on	tumor	growth	could	involve	direct	
effects	on	malignant	cells	and/or	on	leukocytes.	To	investigate	mechanisms	of	action	of	
the	anti-CCR4	antibody,	we	studied	single	cell	suspensions	from	the	treated	tumors.	
Several	cell	types	were	positive	for	CCR4	staining	in	control	tumors:	macrophages	
(CD45+	F4/80+	CD11b+)	and	different	T	cell	subtypes,	such	as	CD4+	(CD45+	CD3+	CD4+	
FoxP3-),	CD8+	lymphocytes	(CD45+	CD3+	CD8+)	and	Tregs	(CD45+	CD3+	CD4+	FoxP3+)	
(Supplementary	Figure	4).	NK	cells	were	also	weakly	positive	for	CCR4	staining	
(Supplementary	Figure	4).	Compared	to	the	leukocyte	populations,	CD45-	cells,	which	
contain	the	malignant	cell	population,	were	only	weakly	positive	for	CCR4	
(Supplementary	Figure	4).	
As	tumor	associated	macrophages	(TAMs)	showed	expression	of	CCR4,	we	first	studied	
the	numbers	and	phenotype	of	these	cells.	The	number	of	TAMs	(gated	as	CD45+	CD11+	
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CD11b+	F4/80+)	per	mg	of	tumor	did	not	differ	significantly	between	Affi-5-treated	and	
control-treated	tumors	(Figure	3A).	However,	the	phenotype	of	the	macrophages	was	
affected	by	treatment.	TAMs	from	Affi-5	treated	mice	expressed	significantly	higher	
levels	of	MHCII	and	lower	levels	of	mannose	receptor	(MR)	compared	to	TAMs	from	
control-treated	mice	(Figure	3B,	C).	In	the	spectrum	of	phenotype	of	macrophage	
activation,	low	MHCII	expression	and	high	MR	levels	are	associated	with	an	‘M2’	
phenotype,	which	promotes	tissue	repair	and	cell	proliferation	(20).	Conversely,	high	
MHCII	expression	and	low	MR	expression	are	characteristic	of	an	‘M1’	macrophage	
phenotype,	associated	with	anti-tumor	activity.	To	further	characterise	the	TAM	
phenotype,	we	extracted	mRNA	from	macrophages	from	Affi-5	and	control-treated	
tumors	and	analysed	them	for	arginase	and	inducible	nitric	oxide	synthase	(NOS2)	
expression.	The	arginase:	NOS2	expression	ratio	was	significantly	lowered	by	anti-CCR4	
treatment	(Figure	3D).	Purified	Affi-5	treated	macrophages	also	showed	increased	
intracellular	TNF,	further	evidence	for	an	‘M1’	cytotoxic	phenotype	(Figure	3E).	Taken	
together,	these	data	imply	that	the	phenotype	of	macrophages	from	anti-CCR4	treated	
tumors	was	altered	compared	to	isotype	control-treated	tumors	and	displayed	several	
characteristics	associated	with	an	anti-tumor	response.	
We	next	asked	if	CCR4	inhibition	could	have	similar	activities	in	another	mouse	cancer	
model,	testing	Affi-5	in	the	B16	melanoma	model.	As	shown	in	Supplementary	Figure	5,	
treatment	altered	the	tumor-associated	macrophage	phenotype	with	a	significant	
increase	in	MHC	Class	II	in	myeloid	cells	in	two	separate	experiments	(Supplementary	
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Figure	5A).	There	was,	however,	no	effect	on	MR	expression	(Supplementary	Figure	5B)	
or	tumor	weight	(Supplementary	Figure	5C)	in	this	rapidly	growing	model.	
	
Actions	of	the	anti-CCR4	antibody	on	T	cells	in	the	tumor	microenvironment	
We	next	examined	changes	among	the	CD3+	T	cells,	which	were	also	positive	for	CCR4	
in	the	RENCA	tumor	microenvironment.	The	number	of	CD3+	cells	per	mg	of	tumor	was	
significantly	higher	in	Affi-5-treated	tumors	compared	to	controls	(Figure	4A).	As	CCR4	
has	been	implicated	in	the	recruitment	of	Tregs	at	tumor	sites	(12,	13),	we	hypothesised	
that	treatment	with	anti-CCR4	would	reduce	the	number	of	CCR4+	Tregs,	as	observed	in	
adult	T-cell	leukemia	patients	treated	with	mogamulizimab	(18).	However,	the	number	
of	Tregs	per	mg	of	tumor	was	higher	in	anti-CCR4	treated	tumors	(Figure	4B).	Also	the	
number	of	CD4	effector	cells	and	CD8	cells	per	mg	of	tumor	was	increased	with	
treatment	(Figure	4B).	As	a	result	of	these	changes,	the	ratios	of	CD4	T	effector	or	CD8	T	
cells	to	Tregs	in	tumors	were	unaffected	by	Affi-5-treatment	(Figure	4C).	
However,	there	was	an	increase	in	the	amount	of	Th1	cytokines	compared	to	Th2	
cytokines	in	the	Affi-5-treated	tumor	lysates	(Figure	4D),	which	could	help	explain	the	
M2/M1	switch	observed	in	the	TAMs.		
We	next	explored	in	more	detail	the	phenotype	of	CD4	effector	and	CD8	cells.	The	
number	of	CD4	cells	positive	for	IFNγ	expression	was	increased	in	treated	tumors	(Figure	
4E),	while	it	was	unaltered	for	the	CD8	cells	(Figure	4F).	Moreover,	CD8	staining	for	
granzyme	B	was	not	significantly	altered	by	treatment	(Figure	4G).	Collectively,	these	
data	suggested	a	role	for	CD4	cells	in	the	anti-tumor	activity	of	the	anti-CCR4	antibody.	
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Other	treatment-induced	changes	to	tumor-infiltrating	leukocyte	populations	
We	observed	repeatedly	a	significant	increase	in	tumor	NK	cells	as	a	proportion	of	total	
CD45+	cells	(Figure	5A),	while	the	proportion	of	granzyme	B-positive	NK	cells	was	not	
altered	(not	shown).	The	effects	on	NK	cells	was	due	to	changes	in	cell	number,	as	a	
significant	increase	in	terms	of	NK	cells/mg	tumor	could	be	observed	(p=0.03)	(Figure	
5B).	Also	myeloid	derived	suppressor	cells	(MDSCs),	characterised	as	CD45+	CD11b+	
Gr1+,	constituted	a	reduced	percentage	of	the	CD45+	infiltrate	in	tumors	from	treated	
mice	compared	to	control-treated	(Figure	5C),	as	there	were	less	granulocytic	(Gr1high)	
and	monocytic	(Gr1int)	MDSCs	in	treated	tumors.	As	for	the	MDSCs	cells	there	was	some	
variability	between	experiments	in	terms	of	numbers	of	cells	so	we	have	expressed	the	
results	as	fold	change	of	cells/mg	of	tumor.	Pooling	results	from	four	experiments	we	
see	a	significant	reduction	in	treated	tumors	(p=0.017)	(Figure	5D).	A	similar	reduction	
of	granulocytic	(Gr-1high)	and	monocytic	(Ly6Chigh)	MDSCs	was	seen	in	the	spleen	of	
treated	mice	compared	to	control	mice	(Figure	5E).	To	determine	whether	the	
accumulated	CD11b+	Gr1+	have	a	suppressive	phenotype	and	could	really	be	identified	
as	MDSCs,	we	performed	immunosuppression	assays	using	T	cells	as	effectors.	
Increasing	amounts	of	MDSCs	from	the	tumors	of	untreated	mice	effectively	suppressed	
proliferation	of	activated	CD4	and	CD8	cells	isolated	from	naïve	splenocytes	(Figure	5F).	
Similarly,	splenic	MDSCs	isolated	from	tumor-bearing	mice	suppressed	proliferation	of	
CD4	and	CD8	cells	(not	shown).	
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Further	investigation	of	CCR4	receptor	on	tumor	CD4+	T	cells	
As	in	our	model	we	observed	changes	to	cells	of	both	the	adaptive	and	innate	immune	
response,	and	some	of	our	evidence	pointed	to	involvement	of	CD4+	T	cells,	we	wanted	
to	better	understand	the	interplay	between	these	different	components.	Affi-5	did	not	
inhibit	RENCA	tumor	growth	in	T-cell	deficient	nude	mice	(Figure	6A)	and	there	was	also	
no	effect	on	macrophage	phenotype	or	extent	of	NK	cell	infiltrate	in	tumors	in	nude	
mice	(Figure	6B-D).	This	suggested	that	adaptive	immunity,	especially	via	CD4+	T	cells,	
was	upstream	of	the	actions	on	the	cells	of	the	innate	immune	system.		
To	further	investigate	a	role	for	CD4	T	cells	in	the	anti-tumor	actions	of	Affi-5,	we	
combined	this	agent	with	a	neutralising	antibody	to	MHC	Class	II.	This	completely	
abrogated	the	effects	of	the	anti-CCR4	antibody	on	RENCA	tumor	weight	(Fig	6E),	
macrophage	MHC	Class	II	(Figure	6F)	and	mannose	receptor	expression	(Figure	6G)	and	
percentage	of	NK	cells	in	the	tumor	microenvironment	(Figure	6H).		
We	concluded	that	CD4	T	cells	are	essential	mediators	of	the	actions	of	the	anti-CCR4	
receptor	antibody	Affi-5,	and	were	required	for	the	observed	changes	in	macrophage	
phenotype	and	proportion	of	NK	cells.	
	
CCR4	function	in	normal	T	cells	
Our	results	led	us	to	question	whether	CCR4	might	be	involved	in	direct	regulation	of	
Th1	and	Th2	responses	in	normal	CD4+	T	cells.	To	explore	this,	we	developed	an	in	vitro	
assay	in	which	CD4+	T	cells	were	purified	from	splenocytes	of	healthy	mice,	and	
polarized	to	a	Th1	response	with	IL-12	and	IL-2	in	the	presence	of	anti-CD3	and	anti-
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CD28	beads.	This	treatment	stimulated	production	of	IFNγ	over	the	course	of	three	
days.	When	CCL17	was	added	to	the	CD4+	cells	one	day	after	the	initial	stimulation,	a	
significant	reduction	in	the	production	of	IFNγ	was	observed	(Figure	7A).	Although	
CCL22	produced	a	similar	trend,	it	was	markedly	weaker	than	CCL17	in	inhibiting	Th1	
polarization	(Figure	7A).	The	action	of	CCL17	on	CD4+	cells	in	vitro	was	abolished	by	
addition	of	the	anti-CCR4	antibody	(Figure	7B,	C).	These	results	indicate	that	CCL17	
might	play	a	role	in	directly	inhibiting	the	Th1	response,	and	provide	more	mechanistic	
insight	into	the	action	of	Affi-5.	CCL17	in	the	tumor	microenvironment	might	be	
secreted	by	many	cell	types,	among	which	M2	polarized	macrophages	(21).	To	support	
this	hypothesis	we	measured	mRNA	levels	for	CCL17	and	22	in	the	different	cell	
populations	of	the	tumor	microenvironment.	Macrophages	showed	the	highest	
expression	of	the	two	chemokines	(Supplementary	Figure	6),	although	a	contribution	
from	other	cell	types	cannot	be	excluded.	
	
Is	antibody-dependent	cell-mediated	cytotoxicity,	ADCC,	involved	in	the	anti-tumor	
action	of	the	anti-CCR4	antibody?	
Finally,	as	ADCC	is	implicated	in	the	mechanisms	of	action	of	the	anti-human	CCR4	
antibody	currently	used	clinically	in	treatment	of	haematological	malignancies	(16),	we	
investigated	the	role	of	ADCC	in	the	actions	of	Affi-5.	While	it	is	possible	that	murine	Fc	
receptors	would	interact	with	a	human	antibody	(22),	both	a	defucosylated	(which	was	
used	in	all	the	experiments	presented	up	to	this	point)	and	fucosylated	version	of	Affi-5	
antibody	had	similar	and	significant	anti-tumor	effects	(Figure	8A).	Moreover,	the	CCR4	
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antagonist	Affi-5	retained	anti-tumor	activity	on	RENCA	cells	in	which	CCR4	was	silenced	
by	shRNA	(Figure	8B,	C).	This	result	indicates	that	the	anti-tumor	effect	of	Affi-5	occurs	
primarily	through	modulation	of	non-malignant	cells	in	the	tumor	microenvironment.	
This	is	not	entirely	unexpected	since	in	vivo	CD45-	cells,	which	would	comprise	the	
RENCA	cells,	expressed	low	levels	of	CCR4	(Supplementary	Figure	4).	However,	as	this	
antibody	has	a	reported	ADCC	activity	against	human	lymphoma	cells	(19),	it	may	act	by	
ADCC	on	other	tumor	cells	where	CCR4	expression	is	higher.	
	
Levels	of	PD-L1	and	CTLA4	after	treatment	
Immune	checkpoint	targeting	has	proven	to	be	a	promising	approach	in	the	treatment	
of	RCC.	Therefore	we	investigated	whether	the	anti-CCR4	treatment	had	an	impact	on	
immune	checkpoint	ligands.	As	shown	in	Supplementary	Figure	7,	CTLA4	expression	on	
Tregs,	and	PD-L1	expression	on	macrophages,	CD3+	T	cells	and	CD45-	cells	was	retained	
after	anti-CCR4	treatment.	This	would	suggest	that,	as	the	anti-CCR4	treatment	displays	
novel	actions	on	different	components	of	the	immune	infiltrate,	it	could	be	a	good	
candidate	to	be	administered	together	with	promising	immune	checkpoint	inhibitors.	
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Discussion		
In	this	study,	we	provide	a	comprehensive	analysis	of	the	expression	of	the	chemokine	
receptor	CCR4	and	its	ligands	CCL17	and	CCL22	in	a	solid	tumor.	We	present	evidence	
that	CCR4	is	expressed	at	significant	levels	in	renal	cancer	biopsies,	where	it	is	
associated	with	the	extent	of	immune	infiltrate.	Also	CCL17	and	CCL22	expression	is	
altered	in	renal	cancer	tissue	and	in	the	plasma	of	patients.	In	fact,	a	high	CCL17:CCL22	
ratio	in	plasma	is	associated	with	a	worse	prognosis.	This	is	reminiscent	to	what	
observed	in	other	solid	tumors,	where	there	is	high	CCR4	expression	that	is	generally	
associated	with	a	poor	prognosis	(14)	(15).	CCL22	is	also	detected	in	the	tumor	
microenvironment	of	ovarian,	hepatocellular	and	breast	cancer	(10)	(12,	13).	Our	work	
is	further	supported	by	a	recent	multivariate	analysis	of	CCR4	expression	in	53	RCC	
patient	biopsies	where	CCR4	expression	was	an	independent	risk	factor	for	poor	
prognosis	and	overall	survival	(23).	Taken	together,	these	observations	suggest	that	
CCR4	is	an	attractive	therapeutic	target	in	solid	cancers.		
In	the	current	work,	we	have	not	considered	a	role	for	the	chemokines,	CCL2	and	CCL5,	
that	may	also	bind	to	CCR4	as	CCL17	and	22	have	the	highest	affinity	for	the	receptor	
but	in	future	studies	it	would	be	interesting	to	assess	the	effect	of	CCR4	inhibitions	on	
their	local	and	systemic	levels.	
In	this	study	we	report	for	the	first	time	that	an	anti-CCR4	antibody	has	activity	in	a	solid	
cancer	model.	As	CCR4	is	expressed	on	a	number	of	different	immune	cells,	we	had	
expected	that	the	CCR4	antibody	would	reduce	the	number	of	tumor-infiltrating	
leukocytes	as	part	of	its	mechanism	of	action,	but	this	did	not	occur.	In	particular,	we	
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did	not	observe	an	effect	on	the	number	of	infiltrating	Tregs,	which	are	thought	to	be	
recruited	though	CCR4	in	the	tumor	microenvironment	of	different	tumor	types	(11)	
(13)	(12).	In	fact	the	antibody	caused	unexpected	changes	in	the	phenotype	of	myeloid	
cells	in	the	RENCA	tumor	microenvironment	from	potentially	pro-	to	anti-tumor.	Tumor	
associated	macrophages	mainly	consist	of	a	population	with	little	cytotoxicity	for	tumor	
cells	because	of	their	limited	production	of	NO	and	proinflammatory	cytokines.	At	the	
same	time,	TAMs	also	possess	poor	antigen-presenting	capability	(20).	This	has	led	to	
the	notion	that	depleting	TAMs	from	the	tumor	microenvironment	is	an	interesting	
target	in	cancer	therapy.	However,	it	was	shown	recently	that	inhibition	of	the	
macrophage	cell	surface	receptor	CSF1R	with	a	small	molecule	inhibitor	in	a	model	of	
glioblastoma	was	able	to	reduce	tumor	progression	by	reducing	the	M2	polarization	of	
TAMs	(24).	This	work	proved	that	modification	of	TAM	tumor-promoting	functions	may	
have	a	significant	impact	on	tumor	growth	and	that	depletion	is	not	strictly	necessary	
for	an	effective	TAM-targeted	therapy.	In	our	work,	the	use	of	an	anti-CCR4	antibody	
achieves,	through	a	different	mechanism	of	action,	a	similar	change	of	TAM	phenotype,	
which	results	in	a	reduction	of	tumor	growth.	There	is	an	interesting	human	correlate	in	
renal	cancer	to	our	experimental	data,	suggesting	that	stimulating	an	M2/Th2	to	
M1/Th1	response	may	be	of	therapeutic	value.	In	a	recent	analysis	of	the	intra-tumoral	
immunologic	profile	of	RCC	biopsies,	M2	macrophage	markers	correlated	with	a	poor	
prognosis	and	tumor	iNOS	mRNA	levels	with	a	good	prognosis	(25).	To	confirm	the	
importance	of	macrophages	in	the	mechanism	of	action	of	Affi-5,	a	depletion	
experiment	with	clodronate	liposomes	was	set	up,	but	the	partial	depletion	of	the	
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macrophages	was	accompanied	by	an	M1	polarization	of	the	remaining	macrophages	
(not	shown),	thus	invalidating	this	model	for	testing	our	hypothesis.	The	potential	of	the	
anti-CCR4	antibody	was	also	suggested	in	the	B16	melanoma	experiments	where	we	
found	an	increase	in	Class	II	MHC	expression.	However,	this	‘partial	switch’	was	not	
enough	to	generate	an	anti-tumor	effect.		
As	part	of	the	multiple	effects	of	the	anti-CCR4	antibody,	we	also	observed	a	significant	
increase	in	NK	cells,	as	well	as	reduction	in	MDSCs	and	circulating	CCL17,	which	can	
additionally	contribute	to	decreased	tumor	growth.	To	determine	the	contribution	of	
these	different	populations	infiltrating	the	tumors,	we	have	extensively	attempted	to	
deplete	NK	cells	and	MDSCs	in	this	model.	However,	while	systemic	depletion	was	
successful,	we	never	obtained	a	satisfactory	depletion	in	the	tumor	microenvironment.		
As	proven	by	the	experiment	in	nude	mice,	these	multiple	effects	are	not	directly	
mediated	by	leukocytes	of	the	innate	immune	system,	but	are	dependent	on	the	
adaptive	immune	system.	Moreover,	disrupting	the	MHCII:	TCR	interaction	abolished	
the	therapeutic	effect	of	the	anti-CCR4	antibody	and	also	impacted	on	innate	immunity	
thus	proving	an	essential	role	for	CD4	cells,	linked	to	their	ability	to	secrete	IFNγ.	Our	in	
vitro	assay	further	supported	the	hypothesis	that	the	CCR4:	CCL17	axis	may	be	involved	
in	maintaining	Th2	responses.	To	our	knowledge,	the	effects	described	here	of	CCR4	
inhibition	in	this	tumor	microenvironment	are	novel.	
We	had	also	predicted	that	the	anti-CCR4	antibody	Affi-5	may	have	ADCC	activity	in	the	
RENCA	model,	especially	on	the	malignant	cells,	but	the	RENCA	cells	in	vivo	had	low	
expression	of	CCR4.	CCR4	is	strongly	expressed	in	several	human	T-cell	malignancies.	
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Mogamulizumab	(KW-0761;	POTELIGIO®),	a	humanised	fucosylated	anti-CCR4	antibody	
that	markedly	enhances	ADCC,	is	used	in	the	treatment	of	patients	with	relapsed	or	
refractory	CCR4-positive	ATL	in	Japan	(26).		Recently	it	also	received	approval	in	Japan	
for	relapsed	or	refractory	CCR4-positive	peripheral	T-cell	lymphoma	(PTCL)	and	
cutaneous	T-cell	lymphoma	(CTCL).	We	could	find	no	evidence	that	Affi-5	was	working	
via	ADCC	in	our	model	system	but	this	does	not	preclude	such	an	action	in	other	models	
or	patients	where	malignant	cells	have	higher	levels	of	CCR4.	Neither,	we	would	
suggest,	does	it	preclude	Mogamulizumab	having	other	actions	in	the	tumor	
microenvironment.	Neither	could	we	find	evidence	that	the	anti-CCR4	antibody	had	
direct	effects	on	the	CCR4	expressing	malignant	cells.	This	may	be	because	the	CD45-	
population,	which	contained	the	malignant	cells,	expressed	low	levels	of	CCR4	in	the	
tumor	microenvironment.	In	addition	RENCA	tumors	growing	in	nude	mice	did	not	
respond	to	the	anti-CCR4	antibody.	As	anti-CCR4	inhibited	RENCA	cell	migration	in	vitro,	
it	is	possible	that	the	antibody	had	an	anti-metastatic	effect	but	it	was	not	possible	to	
measure	this	in	our	model	system.	
In	summary,	we	have	described	here	a	new	therapeutic	strategy	to	target	solid	tumors	
with	a	significant	CCR4	expression	in	the	tumor	microenvironment.	As	targeting	CCR4	in	
haematological	malignancies	has	shown	manageable	side	effects,	this	approach	could	
readily	be	translated	into	the	clinic.	Moreover,	this	opens	the	possibility	for	evaluation	
of	combinations	of	CCR4	inhibition	with	other	immune-modulatory	agents.	Inhibition	of	
CCR4	had	multiple	actions	in	the	RCC	experimental	tumor	microenvironment	–	but	
predominantly	there	was	evidence	of	a	Th2/M2	to	Th1/M1	switch.	CCR4	inhibition	also	
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increased	Class	II	MHC	expression	on	tumor-associated	macrophages	in	the	B16	model.	
As	Tregs	infiltration	or	CD8	activation	were	not	affected	and	the	antibody	did	not	alter	
levels	of	CTLA4	and	PD-L1	in	the	renal	tumor	microenvironment,	there	is	a	strong	
rationale	for	a	combination	with	immune	checkpoint	blockade.	Also	combinations	with	
anti-CD40	agonistic	antibodies	would	be	an	attractive	option,	as	stimulating	
macrophage	activation	in	a	Th1	skewed	environment	may	increase	a	host	anti-tumor	
response.	
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Methods	
Reagents	
Recombinant	human	chemokines	CCL17	(300-30)	and	CCL22	(300-36)	were	purchased	
from	Peprotech	(Rocky	Hill,	NJ).	Recombinant	mouse	CCL17	(529-TR)	and	CCL22	(439-
MD)	were	purchased	from	R&D	Systems	(Minneapolis,	MN).	
RNA	isolation	and	RT-PCR	
RNA	from	sorted	macrophages	was	extracted	with	the	RNeasy	Micro	Kit	(Quiagen,	
Hilden,	Germany)	and	amplified	with	the	Ovation	PicoSL	WTA	System	V2	(NuGen,	San	
Carlos,	CA).	Real-time	RT-PCR	analysis	was	performed	using	TaqMan	assays	(Applied	
Biosystems,	Foster	City,CA):	CCR4	(Hs99999919_m1),	18s	(4310893E),	ArginaseI	
(Mm00440502_m1),	iNOS	(Mm99999062_m1)	with	the	ABI	StepOnePlus	instrument	
(Applied	Biosystems).	
Renal	tissue	and	patient	plasma	samples	
Patients	samples	were	collected	under	the	Ethical	Number	MREC	02/8/78.	Patients	had	
locally	advanced	or	metastatic	renal	cell	carcinoma	(RCC),	who	had	progressed	after	
first-line	cytokine-based	therapy	(for	locally	advanced	disease)	or,	were	intolerant	to	
first	line	cytokine-based	therapy	(for	locally	advanced	or	metastatic	disease).	The	TMA	
was	mainly	comprised	of	clear	cell	renal	carcinomas	(75%),	with	some	biopsies	classified	
as	papillary	renal	cancer.	Clear	cell	renal	carcinomas	were	identified	using	standard	
immunohistochemistry	and	CAIX	staining.	CCR4	was	detected	on	the	malignant	cells	
from	153	of	173	malignant	tumors,	clear	cell	and	non-clear	cell,	in	our	TMA.	Controls	
were	age-matched	individuals	with	no	malignancies.		
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Immunohistochemistry	
Paraffin-embedded	sections	(4	µm)	were	dewaxed	and	dehydrated	and	antigen	retrieval	
was	performed	by	microwaving	sections	in	Antigen	Unmasking	Solution	(Vector,	H-
3300)	for	9	min.	After	blocking	with	the	appropriate	serum,	samples	were	incubated	
overnight	at	4°C	using	primary	antibodies:	CCR4	(ab1669	1:300;	Abcam,	Cambridge,	UK),	
CCL17	(ab182793	1:100;	Abcam),	CCL22	(500-P107	1:20;	Peprotech),	CD3	(A0452,	1:100,	
Dako,	Santa	Clara,	CA),	CD68	(M0876	1:50,	Dako).	Following	incubation	with	a	
biotinylated	secondary	antibody	(anti-goat,	anti-rabbit	or	anti-mouse	IgG,	1:200,	Vector	
Laboratories,	Burlingame,	CA)	for	30	min	at	room	temperature,	antigens	were	revealed	
with	3,3’-diaminobenzidine	(Sigma-Aldrich,	St.	Loius,	MO).	Omission	of	the	primary	
antibody	and	isotype	control	antibody	were	used	as	negative	controls.	The	scoring	for	
intensity	of	staining	on	positive	cells	was	as	follows:	0	(no	expression),	1	(low	
expression)	and	2	(high	expression).		
ELISA	and	Mesoscale	Discovery	System	
Human	CCL17	and	CCL22	were	determined	from	plasma	with	Mesoscale	Discovery	
System	plates	(K151BGC-1	Human	TARC	Ultra-Sensitive	Kit	and	Human	MDC	Ultra-
Sensitive	Kit,	K151BAC,	Mesoscale	Diagnostic,	Rockville,	MD).	Mouse	CCL17	and	CCL22	
were	determined	from	plasma	or	serum	with	Mouse	CCL17/TARC	Quantikine	ELISA	Kit	
(MCC170)	or	Mouse	CCL22/MDC	Quantikine	ELISA	Kit	(MCC220)	from	R&D	Systems.	
Cell	culture	
786-O,	RENCA	and	B16F0	cells	were	either	a	kind	gift	from	the	laboratory	of	Dr	Serafim	
Kiriakidis,	or	from	ATCC.	Cells	were	incubated	at	37°C	in	humidified	air	with	5%	CO2.	
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786-O	cells	were	cultured	in	RPMI	culture	media	containing	10%	foetal	bovine	serum	
(FBS),	1%	penicillin/streptomycin	(p/s)	and	1%	glutamine.	RENCA	culture	medium	was	
further	supplemented	with	1%	glutamine	and	1	mM	sodium	pyruvate.	Renal	cancer	cell	
lines	were	luciferase	labelled	for	in	vivo	experiments.	B16F0	were	cultured	in	Dulbecco's	
Modified	Eagle	Medium	(DMEM)	containing	10%	FBS	and	1%	p/s.	
Migration	assays	
Chemotaxis	was	assayed	using	the	Falcon	PET	Cell	Culture	Inserts,	8	µm	pore	(353182,	
Becton	Dickinson,	Franklin	Lanes,	NJ).	786-O	cells	were	seeded	in	the	upper	chamber	at	
1x105	in	0.5	ml	serum-free	RPMI	and	1	ml	of	medium	alone	or	supplemented	with	
recombinant	chemokines	was	added	to	the	lower	chamber.	RENCA	cells	were	seeded	at	
2x105	in	medium	containing	1%	serum.	After	overnight	incubation	at	37°C	and	5%	CO2	
cells	on	the	upper	surface	of	the	filter	were	removed	and	migrated	cells	on	the	lower	
surface	were	stained	with	DiffQuik	(Dade	Behring,	Deerfield,	IL).	For	each	insert,	the	
number	of	migrated	cells/field	(40x	for	786-O,	20x	for	RENCA)	was	counted.	The	assays	
were	performed	in	triplicate.	
Anti-CCR4	antibody		
Affi-5	is	a	human	IgG1	antibody	antagonist	of	CCR4.	This	antibody	is	also	referred	to	as	
503	(18).	It	was	produced	by	transient	transfection	of	expression	vectors	into	HEK-293T	
cells	with	FuGENE	transfection	reagent	(Promega,	Madison,	WI).	The	ADCC	enhanced	
(defucosylated)	variant	was	produced	using	a	selective	class	I	a-mannosidase	inhibitor,	
kifunensine	(Sigma-Aldrich)	that	was	added	to	the	culture	medium	at	a	concentration	of	
100ng/ml.	The	antibody	was	then	purified	using	standard	conditions	and	formulated	in	
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20mM	Phosphate	buffered	saline	145mM	NaCl	pH7.2.	It	was	diluted	to	the	required	
concentration	in	the	same	buffer.		
In	vivo	experiments	
For	the	renal	model,	6-8	week	old	female	Balb/c	or	Balb/c	nu/nu	mice	from	Charles	
River	(UK)	were	injected	orthotopically	with	1x105	luciferase-labelled	RENCA	cells	
resuspended	in	Matrigel	(354248,	BD	Biosciences,	Becton	Dickinson,	Franklin	Lanes,	NJ)	
into	the	kidney	capsule	of	the	left	kidney.	Affi-5	and	the	appropriate	isotype	control	
where	injected	intra-peritoneally	twice	weekly	at	10	or	20	mg/kg,	starting	at	day	2	after	
surgery.		
Tumor	weight	was	determined	at	the	end	of	the	experiment	by	subtracting	the	right	
kidney	weight	from	the	weight	of	the	tumor-bearing	left	kidney.	
Tumor	growth	was	monitored	after	administration	of	luciferin	(3	mg/mouse,	Sigma-
Aldrich)	with	the	IVIS	Imaging	System	100	(Xenogen	Biosciences,	Cranbury,	NJ).	Mice	
were	sacrificed	between	day	17	and	day	12	post-surgery.	
The	anti-MHCII	blocking	antibody	(clone	M5/114)	and	the	isotype	control	(LTF-2)	were	
obtained	from	BioXCell	(West	Lebanon,	NH)	and	administered	i.p.	at	10	mg/kg	one	day	
prior	to	surgery	and	three	times/week	thereafter.	
For	the	melanoma	model,	8-12	week	old	C57/BL6	mice	from	Charles	River	(UK)	were	
injected	subcutaneously	with	1x105	B16F0	cells	resuspended	in	PBS.	Affi-5	and	the	
appropriate	isotype	control	where	injected	intra-peritoneally	twice	weekly	at	20	mg/kg,	
starting	at	day	2	after	surgery.	Mice	were	sacrificed	at	day	18	post-injection.	
Flow	cytometry	and	sorting	
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Human	cell	lines	were	dissociated	using	cell	dissociation	buffer	(Invitrogen)	and	stained	
with	anti-CCR4	(R&D	systems,	FAB1567P)	or	IgG2B	isotype	control	(R&D	Systems).	After	
washing,	cells	were	incubated	with	Alexa-594	anti-mouse	antibody	(Invitrogen,	
Carlsbad,	CA).	Intracellular	staining	was	achieved	using	saponin	permeabilisation	before	
antibodies	against	CCL17	and	CCL22	were	applied	(R&D	Systems,	IC364IP	and	IC3361P	
respectively).	RENCA	murine	cells	were	stained	with	Affi-5	or	isotype	control.	After	
washing,	cells	were	incubated	with	Alexa488	anti-human	antibody	(Invitrogen).	
Tumor-bearing	left	kidneys	were	chopped	and	incubated	in	2	mg/ml	collagenase	V	
(Sigma-Aldrich),	and	25	µg/ml	DNAse	(Roche,	Basel,	Switzerland),	in	HBSS	(Sigma-
Aldrich)	for	45	min	at	37˚C,	5%	CO2.	Tumor-bearing	kidneys	were	selected	to	be	
representative	of	the	average	tumor	weight	of	the	treatment	group	they	belonged	to.	
The	lysate	was	strained	with	70	µm	strainers	(Fisher	Scientific,	Loughborough,	UK),	and	
red	blood	cells	were	lysed	(BD	Pharm	Lyse,	BD	Bioscience).	Cells	were	counted	and	
6x106	cells	were	stained	in	PBS	+	2%	heat	inactivated	FBS	+	2	mM	EDTA	after	blocking	
with	αCD16/CD32	(14-0161,	eBioscience,	San	Diego,	CA)	for	15	min.	Staining	antibodies	
were	diluted	1:200	unless	differently	specified:	αCD45	(48-0451,	eBioscience),	αFoxP3	
(56-5773,	eBioscience),	αCD3	(45-0031,	eBioscience),	αCD4	(560783,	BD	Bioscience,	
1:300),	αCD8	(48-0041,	eBioscience,	1:300),	αLy-6C	(45-5932,	eBioscience),	αLy-6G	(Gr-
1)	(35-5931,	eBioscience),	αCD49b	(108918,	BioLegend,	San	Diego,	CA),	αF4/80	(47-
4801,	eBioscience,	1:150),	αCD11b	(11-0112,	eBioscience),	αMMR	(141706,	BioLegend),	
αMHCII	(17-5321,	eBioscience),	αCCR4	(131214,	BioLegend),	αCD4	(560783,	BD	
Biosciences,	1:300),	αKi67	(612472,	BD	Biosciences,	5	µl/staining).	Appropriate	isotype	
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control	antibodies	were	used	to	generate	Fluorescence	Minus	One	controls.	Viability	
was	assessed	with	Fixable	Viability	Dye	eFluor780	or	506	(eBioscience)	diluted	1:1000.	
Staining	was	performed	for	30	min	at	4˚C.	Cells	were	washed,	fixed	in	2%	formaldeyde,	
and	analysed	using	a	BD	LSR	Fortessa	cytometer.	Analysis	was	performed	with	the	
FlowJo	software	(Ashland,	OR).	
For	the	sorting	of	TAMs,	tumors	were	dissected	and	dissociated	as	described	above.	
Cells	were	stained	in	PBS	+	2%	heat	inactivated	FBS	+	2	mM	EDTA	after	blocking	with	
αCD16/CD32	(14-0161,	eBioscience)	for	15	min.	Staining	antibodies	were	from	
eBioscience	and	were	diluted	1:200	unless	differently	specified:	αCD45	(48-0451),	
αLy6G	(Gr-1)	(35-5931),	αF4/80	(47-4801,	1:150)	αCD11b	(11-0112),	for	30	min	at	4˚C.	
DAPI	(2.5	µg/ml)	was	added	prior	to	sorting,	which	was	performed	with	a	BD	FACSARIA	
II	cell	sorter.	
Suppression	assay	
Tumors	were	dissociated	as	for	flow	cytometry	staining	and	pooled.	MDSCs	were	
purified	according	to	manufacture’s	instructions	using	the	Myeloid-Derived	Suppressor	
Cell	Isolation	kit	(Miltenyi	Biotech,	Bergish	Gladbach,	Germany).	Naïve	CD3	were	
isolated	from	spleen	of	healthy	mice	using	the	Dynabeads	FlowComp	Pan	T	kit	
(Invitrogen).	Before	stimulation,	CD3	cells	were	prelabelled	with	5	µM	CSFE	
(eBioscience)	for	5	min	at	37˚C	in	medium	and	washed.	Part	of	the	cells	was	left	
without	stimulus,	while	the	remaining	was	stimulated	with	anti-CD3	anti	CD28	coated	
beads	(Dynabeads	Mouse	T-Activator	CD3/CD28,	Invitrogen)	at	a	ratio	1:2	(beads:CD3)	
and	plated	(5x104/well)	in	round-bottom	96-wells.	MDSCs	were	added	to	the	wells	at	a	
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ratio	of	10:1,	1:1,	1:2,	1:8	(CD3:MDSCs)	and	incubated	for	three	days.	At	the	end	of	the	
incubation	period,	cells	were	collected	and	stained	for	viability,	CD11b,	CD3,	CD4	and	
CD8	for	flow	cytometry.	Staining	was	performed	for	30	min	at	4˚C.	Cells	were	washed,	
fixed	in	2%	formaldeyde,	and	analysed	using	a	BD	LSR	Fortessa	cytometer.	Analysis	
was	performed	with	the	FlowJo	software.	CD4	or	CD8	cells	that	had	undergone	at	least	
one	cycle	of	cell	division	were	gated	as	proliferating.	
Intracellular	flow	cytometry	
Tumors	were	dissected	and	dissociated	as	described	above.	For	macrophage	staining,	
cells	were	plated	(0.5x106/500	µl	in	a	24	well-plate)	and	incubated	overnight	with	
Brefeldin	A	(Sigma-Aldrich)	20	µg/ml.	The	following	day,	cells	were	stained	in	PBS	+	2%	
heat	inactivated	FBS	+	2	mM	EDTA	after	blocking	with	αCD16/CD32	1:200	(14-0161,	
eBioscience)	for	15	min.	Staining	antibodies	were	from	eBioscience	and	were	diluted	
1:200	unless	differently	specified:	αCD45	(48-0451),	αLy-6G	(Gr-1)	(35-5931),	αF4/80	
(47-4801,	1:150)	αCD11b	(11-0112),	and	Fixable	Viability	Dye	eFluor780	or	506	
(eBioscience)	diluted	1:1000	for	30	min	at	4˚C.	After	washing,	cells	were	fixed	in	
Intracellular	Fixation	Buffer	(eBioscience)	for	20	min	at	RT.	Cells	were	further	
permeabilized	and	stained	in	Permeabilization	buffer	with	αTNF	(11-7321-81,	
eBioscience)	1:75	in	25	µl,	or	the	appropriate	isotype	control,	for	30	min	at	4˚C.	After	
washing,	cells	were	analysed	using	a	BD	LSR	Fortessa	cytometer.	Analysis	was	
performed	with	the	FlowJo	software.	For	CD4/CD8	staining,	lymphocytes	were	purified	
using	Dynabeads	FlowComp	Mouse	Pan	T	(Invitrogen)	according	to	instructions,	plated	
in	500	µl	in	a	24-well	plate,	incubated	with	PMA	(50	ng/ml,	Sigma-Aldrich)	and	
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ionomycin	(1	µg/ml,	Sigma-Aldrich)	for	1	hour,	and	further	incubated	in	the	presence	of	
Brefeldin	A	(20	µg/ml,	Sigma-Aldrich)	for	3	hours.	At	the	end	of	the	incubation,	cells	
were	washed,	blocked	as	above,	and	stained	with	αCD3	(45-0031,	1:200),	αCD8	(48-
0041,	1:300),	αCD4	(47-0041,	1:200),	from	eBioscience,	and	Fixable	Viability	Dye	
eFluor506	1:1000,	fixed	in	2%	formalin,	and	stored	overnight	at	4˚C.	The	day	after,	cells	
were	permeabilized	and	stained	with	αIFNγ	(17-7311,	1:100)	and	αTNF	(11-7321-81,	
1:75),	or	the	appropriate	isotype	controls,	from	eBioscience	in	25	µl	in	Permeabilization	
buffer	for	30	min	at	4˚C,	and	further	processed	and	analyzed	as	specified	above.	
Cytokine	expression	
Frozen	tumors	were	lysed	with	a	GentleMACS	M	tube	(Miltenyi)	in	PBS	with	Complete	
Protease	Inhibitors	(Roche).	Triton-X	100	was	added	(1%),	lysates	were	cleared	by	
centrifugation	and	applied	to	ProteomeProfiler	Mouse	Cytokine	Array	Panel	A	
membranes	(R&D	System).	An	equivalent	amount	of	200	µg	tumor	lysate	was	incubated	
according	to	manufacturer’s	instructions.	Film	exposures	were	quantified	using	ImageJ	
software	subtracting	a	lane	background.		
In	vitro	Th1	polarization	assay.		
Splenocytes	from	healthy	Balb/c	mice	were	obtained	by	mashing	spleens	through	a	70	
µm	strainer	and	lysis	of	red	blood	cells.	CD4+	cells	were	purified	with	the	Miltenyi		CD4+	
T	cell	purification	kit	according	to	manufacturer’s	instructions.	CD4+	cells	were	
resuspended	in	IMDMEM	10%FBS,	50	µM	b-mercaptoethanol,	glutammine	8	mM,	and	
stimulated	with	beads	1:1	Dynabeads®	Mouse	T-Activator	CD3/CD28	(Invitrogen),	
mouse	IL-2	20	ng/ml	and	mouse	IL-12	5	ng/ml	(from	RnD	System).	The	day	after,	the	
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indicated	concentrations	of	CCL17	or	CCL22	in	combination	with	Affi-5	(30	µg/ml)	were	
added	to	the	plate.	Experiments	with	Affi-5	were	performed	in	Corning	Ultra-low	
attachment	plasticware	(Cornig	Life	Sciences,	Cornig,	NY).	Cells	were	stimulated	with	
Restimulation	cocktail	plus	transport	inhibitor	from	ebioscience	for	5	hours,	and	stained	
for	30	min	at	4˚C	with	αCD16/CD32	(14-0161,	eBioscience,	1:200),	Fixable	Viability	Dye	
efluor450	1:1000,	αCD4	(560783,	BD	Horizon	CD4,	BD	Bioscience,	1:300)	in	50	µl	FACS	
buffer.	After	washing,	cells	were	permeabilized	and	stained	with	αIFNγ	(17-7311,	
eBioscience,	1:100),	or	isotype	control.	After	washing,	cells	were	analysed	using	a	BD	
LSR	Fortessa	cytometer.	
Immunofluorescence		
Renal	carcinoma	786-O	and	RENCA	cells	were	cultivated	on	a	chamber	slide	(Nalge	Nunc	
International,	Penfield,	NY)	for	1-2	days.	Cells	were	then	fixed	for	30	min	with	4%	
formaldehyde	and	permeabalised	with	0.5%	Triton	X-100	in	PBS	for	10	min.	Samples	
blocked	with	1%	BSA	for	2	hours	at	RT,	then	incubated	overnight	at	4˚C	with	25	mg/ml	
of	α-CCR4	(IMG-322,	IMGENEX,	Novus	Biologicals,	Litteton,	CO).	After	washing,	samples	
were	incubated	with	Alexa-594	secondary	antibody,	1:2000	for	2	hours	at	RT.	Finally,	
samples	were	washed	mounted	with	Prolong	Gold	DAPI	(Invitrogen,	P36931).	Cells	were	
then	visualized	using	a	Zeiss	LSM510	confocal	microscope	(Zeiss,	Oberkochen,	
Germany).	
RNA	interference	for	CCR4	in	renal	cancer	cell	lines	
Commercially	available	shRNAs,	based	on	the	pRS	vector,	were	purchased	from	Origene	
Technologies	(Rockville,	MD).	Four	non-overlapping	sequences	were	provided	to	target	
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human	(TR314127)	and	mouse	(TR500386)	CCR4.	A	non-specific	shRNA	sequence	
(shGFP,	TR30003)	and	empty	pRS	vector	(TR20003)	served	as	controls.	Phoenix	
packaging	cell	line	was	transfected	overnight	with	LipofectAMINE	2000	(Invitrogen)	and	
5	µg	of	the	shRNA	plasmid	DNA.	After	an	incubation	with	complete	medium	at	33°C	and	
5%	CO2	for	16	hours,	the	supernatant	was	collected,	filtered,	diluted	8:10	in	RCC	
medium	with	the	addition	of	polybrene.	RENCA	or	786-O	at	30%	confluence	were	
infected	for	10	h	twice	within	48	h.	Virus-infected	cells	were	selected	with	1.5	µg/ml	
puromycin	(InvivoGen).	For	long-term	silencing	in	vivo,	RENCA-luc	cells	were	infected	
with	three	lentiviral	GIPZ	vectors	targeting	mouse	CCR4	from	Thermo	Fisher	Scientific	
(Waltham,	MA).	Viral	particles	were	obtained	by	transfecting	HEK293T	with	Ca-
Phosphate	method	with	21	µg	shRNA	construct,	7	µg	VSVG	construct,	14	µg	HIV	
construct	(from	Addgene,	Cambridge,	MA),	in	a	14-cm	dish,	and	collecting	the	
supernatant	for	24	h.	RENCA-luc	were	infected	for	24	h	in	a	6-well	plate	with	1	ml	
supernatant.	Virus-infected	cells	were	selected	with	0.3	µg/ml	puromycin	(Sigma).	After	
verifying	the	silencing,	cells	infected	with	vector	V3LMM_439088	were	chosen	for	the	in	
vivo	experiment.	
Statistical	analysis	
All	data	are	expressed	as	the	mean	±	the	standard	error	(SE)	of	the	mean.	Differences	
were	considered	significant	at	p	<	0.05,	using	a	Student’s	T-Test	(two-tailed),	ANOVA	
test	or	non-parametric	test	as	appropriate,	performed	with	the	statistical	analysis	
software	Prism.	P	values	are	specified.		
Study	approval	
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Patients	samples	were	collected	under	the	Ethical	Number	MREC	02/8/78.	
All	experimental	procedures	observed	the	guidelines	approved	by	the	ethics	
committees	of	QMUL	under	the	Home	Office	licence	70/7411.	
Acknowledgements	
The	study	was	supported	by	CRUK	programme	grant	C587/A16354	and	a	research	grant	
from	Affitech	AS.	We	would	like	to	thank	Prof.	Yaohe	Wang	(Barts	Cancer	Institute,	
London)	for	his	help	in	setting	up	CCR4,	CCL17	and	CCL22	immunohistochemistry	
staining,	Dr.	David	Gould	(William	Harvey	Research	Institute,	London)	for	luciferase-
labeling	our	renal	cancer	cell	lines,	Dr.	Melania	Capasso	and	Mark	Brown	(Barts	Cancer	
Institute,	London)	for	assistance	with	the	silencing	experiments,	Dr.	Alzbeta	Talarovicova	
(Barts	Cancer	Institute,	London)	for	assistance	with	the	mouse	work,	and	Dr.	Matthew	
McCourt	(Actigen,	Cambridge)	for	helpful	discussion.	
 
Author	Contributions	
CB	designed,	performed,	and	interpreted	most	of	the	experiments,	and	wrote	the	
manuscript.	MNK	designed,	performed,	and	interpreted	the	experiments	shown	in	Fig.	1	
and	Suppl.	Fig.	1-3.	TS,	AM	and	EM	contributed	designing,	performing,	and	interpreting	
some	experiments	and	editing	the	manuscript.	RT	performed	most	of	the	surgery	
experiments.	MJ	conducted	and	analyzed	the	B16	melanoma	studies.	MC	measured	and	
analyzed	the	chemokine	levels	in	patients.	HK	contributed	to	design	of	the	research	
studies.	UBH	and	AD	provided	the	Affi-5	antibody	and	contributed	to	the	design	of	the	
experiments.	LF	and	RWW	contributed	to	the	design	of	the	research	studies	and	editing	
the	manuscript.	TP	provided	patient	samples,	patient	information	and	intellectual	input,	
SQ	contributed	designing	and	interpreting	crucial	experiments	analysing	adaptive	
immunity.	FB	conceived	of,	designed,	and	supervised	the	project	and	experimental	plan,	
interpreted	experiments,	and	wrote	the	manuscript.	
	
	 	
	 33	
References	
1.	 Raman	D,	Sobolik-Delmaire	T,	and	Richmond	A.	Chemokines	in	health	and	
disease.	Exp	Cell	Res.	2011;317(5):575-89.	
2.	 Allavena	P,	Germano	G,	Marchesi	F,	and	Mantovani	A.	Chemokines	in	cancer	
related	inflammation.	Exp	Cell	Res.	2011;317(5):664-73.	
3.	 Mantovani	A,	Savino	B,	Locati	M,	Zammataro	L,	Allavena	P,	and	Bonecchi	R.	The	
chemokine	system	in	cancer	biology	and	therapy.	Cytokine	Growth	Factor	Rev.	
2010;21(1):27-39.	
4.	 Zlotnik	A,	Burkhardt	AM,	and	Homey	B.	Homeostatic	chemokine	receptors	and	
organ-specific	metastasis.	Nat	Rev	Immunol.	2011;11(9):597-606.	
5.	 Balkwill	FR.	The	chemokine	system	and	cancer.	The	Journal	of	pathology.	
2012;226(2):148-57.	
6.	 Bonecchi	R,	Bianchi	G,	Bordignon	PP,	D'Ambrosio	D,	Lang	R,	Borsatti	A,	Sozzani	S,	
Allavena	P,	Gray	PA,	Mantovani	A,	et	al.	Differential	expression	of	chemokine	
receptors	and	chemotactic	responsiveness	of	type	1	T	helper	cells	(Th1s)	and	
Th2s.	J	Exp	Med.	1998;187(1):129-34.	
7.	 Kunkel	EJ,	Boisvert	J,	Murphy	K,	Vierra	MA,	Genovese	MC,	Wardlaw	AJ,	
Greenberg	HB,	Hodge	MR,	Wu	L,	Butcher	EC,	et	al.	Expression	of	the	chemokine	
receptors	CCR4,	CCR5,	and	CXCR3	by	human	tissue-infiltrating	lymphocytes.	Am	J	
Pathol.	2002;160(347-55.	
8.	 Imai	T,	Nagira	M,	Takagi	S,	Kakizaki	M,	Nishimura	M,	Wang	J,	Gray	PW,	
Matsushima	K,	and	Yoshie	O.	Selective	recruitment	of	CCR4-bearing	Th2	cells	
toward	antigen-presenting	cells	by	the	CC	chemokines	thymus	and	activation-
regulated	chemokine	and	macrophage-derived	chemokine.	International	
immunology.	1999;11(1):81-8.	
9.	 Yoshie	O,	and	Matsushima	K.	CCR4	and	its	ligands:	from	bench	to	bedside.	
International	immunology.	2015;27(1):11-20.	
10.	 Curiel	TJ,	Coukos	G,	Zou	L,	Alvarez	X,	Cheng	P,	Mottram	P,	Evdemon-Hogan	M,	
Conejo-Garcia	JR,	Zhang	L,	Burow	M,	et	al.	Specific	recruitment	of	regulatory	T	
cells	in	ovarian	carcinoma	fosters	immune	privilege	and	predicts	reduced	
survival.	Nature	medicine.	2004;10(9):942-9.	
11.	 Jacobs	JF,	Idema	AJ,	Bol	KF,	Grotenhuis	JA,	de	Vries	IJ,	Wesseling	P,	and	Adema	
GJ.	Prognostic	significance	and	mechanism	of	Treg	infiltration	in	human	brain	
tumors.	J	Neuroimmunol.	2010;225(1-2):195-9.	
12.	 Yang	P,	Li	QJ,	Feng	Y,	Zhang	Y,	Markowitz	GJ,	Ning	S,	Deng	Y,	Zhao	J,	Jiang	S,	Yuan	
Y,	et	al.	TGF-beta-miR-34a-CCL22	signaling-induced	Treg	cell	recruitment	
promotes	venous	metastases	of	HBV-positive	hepatocellular	carcinoma.	Cancer	
Cell.	2012;22(3):291-303.	
13.	 Gobert	M,	Treilleux	I,	Bendriss-Vermare	N,	Bachelot	T,	Goddard-Leon	S,	Arfi	V,	
Biota	C,	Doffin	AC,	Durand	I,	Olive	D,	et	al.	Regulatory	T	Cells	Recruited	Through	
CCL22/CCR4	are	Selectively	Activated	in	Lymphoid	Infiltrates	Surrounding	
Primary	Breast	Tumors	and	Lead	to	an	Adverse	Clinical	Outcome.	Cancer	Res.	
2009;69(5):2000-9.	
	 34	
14.	 Li	JY,	Ou	ZL,	Yu	SJ,	Gu	XL,	Yang	C,	Chen	AX,	Di	GH,	Shen	ZZ,	and	Shao	ZM.	The	
chemokine	receptor	CCR4	promotes	tumor	growth	and	lung	metastasis	in	breast	
cancer.	Breast	cancer	research	and	treatment.	2012;131(3):837-48.	
15.	 Lee	JH,	Cho	YS,	Lee	JY,	Kook	MC,	Park	JW,	Nam	BH,	and	Bae	JM.	The	chemokine	
receptor	CCR4	is	expressed	and	associated	with	a	poor	prognosis	in	patients	with	
gastric	cancer.	Annals	of	surgery.	2009;249(6):933-41.	
16.	 Ishida	T,	Joh	T,	Uike	N,	Yamamoto	K,	Utsunomiya	A,	Yoshida	S,	Saburi	Y,	
Miyamoto	T,	Takemoto	S,	Suzushima	H,	et	al.	Defucosylated	anti-CCR4	
monoclonal	antibody	(KW-0761)	for	relapsed	adult	T-cell	leukemia-lymphoma:	a	
multicenter	phase	II	study.	J	Clin	Oncol.	2012;30(8):837-42.	
17.	 Ogura	M,	Ishida	T,	Hatake	K,	Taniwaki	M,	Ando	K,	Tobinai	K,	Fujimoto	K,	
Yamamoto	K,	Miyamoto	T,	Uike	N,	et	al.	Multicenter	phase	II	study	of	
mogamulizumab	(KW-0761),	a	defucosylated	anti-cc	chemokine	receptor	4	
antibody,	in	patients	with	relapsed	peripheral	T-cell	lymphoma	and	cutaneous	T-
cell	lymphoma.	J	Clin	Oncol.	2014;32(11):1157-63.	
18.	 Sugiyama	D,	Nishikawa	H,	Maeda	Y,	Nishioka	M,	Tanemura	A,	Katayama	I,	Ezoe	S,	
Kanakura	Y,	Sato	E,	Fukumori	Y,	et	al.	Anti-CCR4	mAb	selectively	depletes	
effector-type	FoxP3+CD4+	regulatory	T	cells,	evoking	antitumor	immune	
responses	in	humans.	Proc	Natl	Acad	Sci	U	S	A.	2013;110(44):17945-50.	
19.	 Hagemann	UB,	Gunnarsson	L,	Geraudie	S,	Scheffler	U,	Griep	RA,	Reiersen	H,	
Duncan	AR,	and	Kiprijanov	SM.	Fully	human	antagonistic	antibodies	against	CCR4	
potently	inhibit	cell	signaling	and	chemotaxis.	PLoS	One.	2014;9(7):e103776.	
20.	 Sica	A,	Larghi	P,	Mancino	A,	Rubino	L,	Porta	C,	Totaro	MG,	Rimoldi	M,	Biswas	SK,	
Allavena	P,	and	Mantovani	A.	Macrophage	polarization	in	tumour	progression.	
Semin	Cancer	Biol.	2008;18(5):349-55.	
21.	 Porta	C,	Rimoldi	M,	Raes	G,	Brys	L,	Ghezzi	P,	Di	Liberto	D,	Dieli	F,	Ghisletti	S,	
Natoli	G,	De	Baetselier	P,	et	al.	Tolerance	and	M2	(alternative)	macrophage	
polarization	are	related	processes	orchestrated	by	p50	nuclear	factor	kappaB.	
Proc	Natl	Acad	Sci	U	S	A.	2009;106(35):14978-83.	
22.	 Overdijk	MB,	Verploegen	S,	Ortiz	Buijsse	A,	Vink	T,	Leusen	JH,	Bleeker	WK,	and	
Parren	PW.	Crosstalk	between	human	IgG	isotypes	and	murine	effector	cells.	J	
Immunol.	2012;189(7):3430-8.	
23.	 Liu	Q,	Rexiati	M,	Yang	Y,	Wang	WG,	Azhati	B,	Saimaiti	W,	and	Wang	YJ.	
Expression	of	chemokine	receptor	4	was	associated	with	poor	survival	in	renal	
cell	carcinoma.	Medical	oncology.	2014;31(4):882.	
24.	 Pyonteck	SM,	Akkari	L,	Schuhmacher	AJ,	Bowman	RL,	Sevenich	L,	Quail	DF,	Olson	
OC,	Quick	ML,	Huse	JT,	Teijeiro	V,	et	al.	CSF-1R	inhibition	alters	macrophage	
polarization	and	blocks	glioma	progression.	Nat	Med.	2013;19(10):1264-72.	
25.	 Dannenmann	SR,	Thielicke	J,	Stockli	M,	Matter	C,	von	Boehmer	L,	Cecconi	V,	
Hermanns	T,	Hefermehl	L,	Schraml	P,	Moch	H,	et	al.	Tumor-associated	
macrophages	subvert	T-cell	function	and	correlate	with	reduced	survival	in	clear	
cell	renal	cell	carcinoma.	Oncoimmunology.	2013;2(3):e23562.	
26.	 Beck	A,	and	Reichert	JM.	Marketing	approval	of	mogamulizumab:	a	triumph	for	
glyco-engineering.	mAbs.	2012;4(4):419-25.	
	 35	
	
	
Figure	1	
Abnormal	expression	of	CCR4	and	its	ligands	in	human	renal	cancer.	(A)	CCR4	mRNA	was	
measured	by	real-time	RT-PCR	in	renal	cell	cancer,	RCC,	biopsies	and	compared	with	
normal	kidney.	(B)	Levels	of	CCR4	and	its	ligands	CCL17	and	CCL22	were	analysed	by	IHC	
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in	a	tissue	microarray	(TMA)	of	renal	cancer	biopsies	from	human	patients.	Each	biopsy	
was	scored	0	–	no	staining,	1	–	weak	staining,	2	–	strong	staining	for	CCR4,	CCL17	and	
CCL22.	A	total	of	173	biopsy	cores	from	57	patients	were	stained	for	CCR4	and	CCL22,	
and	145	cores	from	48	patients	for	CCL17.	(C,	D,	E)	Plasma	levels	of	CCL17,	CCL22	and	
the	CCL17:22	ratio	in	RCC	patient	plasma	were	compared	to	normal	individuals	of	
matched	age	using	Mesoscale	Discovery	System	Ultra-Sensitive	plates.	(n=47	for	RCC	
patients,	n=26	for	normals,	two-tailed	Student’s	t	test,	***p=	0.0001	for	CCL17,	
***p<0.0001	for	CCL22,	***p<	0.0001	for	CCL17:CCL22).	(F,	G)	Kaplan-Meier	survival	
curves	for	progression	free	survival	(F)	and	overall	survival	(G)	for	RCC	patients	with	
CCL17:CCL22	high	(above	the	median)	or	low	(n=57).	For	progression	free	survival,	
hazard	ratio	0.436,	95%	CI	0.239	to	0.797,	for	overall	survival,	hazard	ratio	0.552,	95%	CI	
0.306	to	0.995.	
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Figure	2	
Anti-CCR4	antibody	Affi-5	has	anti-tumor	activity	in	the	RENCA	RCC	model.	(A)	Migration	
of	RENCA	cells	in	response	to	mouse	CCL17	in	the	presence	of	10	µg/ml	Affi-5	or	isotype	
control	IgG	after	an	incubation	of	16	hours	was	analysed	with	a	migration	assay.	
Significant	difference	compared	to	the	CCL17-induced	migration	in	the	presence	of	
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isotype	control	is	indicated,	two-tailed	Student’s	t	test,	**	p<0.01.	CCL17-induced	
migration	is	significant	compared	to	control	(p<0.05).	One	experiment	representative	of	
three	is	shown.	(B,	C)	Balb/c	mice	were	injected	with	1x105	RENCA-luc	cells	and	treated	
twice	weekly	with	Affi-5	(T)	or	isotype	control	(C)	at	20	mg/kg	starting	48h	after	surgery.	
Mice	were	sacrificed	17	days	after	surgery	and	tumor	weight	was	determined.	
Combined	results	of	six	experiments	are	shown	(n=	42	C,	n=	43	T,	two-tailed	
Student’s	t	test,	p<0.0001).	Chemiluminescence	was	determined	at	day	7,	14,	and	17	
and	one	representative	experiment	is	reported	in	the	graph	and	pictures	as	relative	
luminescence	units	(C)	two-tailed	Student’s	t	test,	*	p=0.029	at	day	17.	(D)	Balb/c	mice	
were	injected	with	1x105	RENCA-luc	cells	and	treated	twice	weekly	with	Affi-5	(T)	or	
isotype	control	(C)	at	10	mg/kg	starting	48h	after	surgery.	Mice	were	sacrificed	17	days	
after	surgery	and	tumor	weight	was	determined.	Combined	results	of	six	experiments	
are	shown	(n=	39	C,	n=	43	T,	two-tailed	Student’s	t	test,	p<0.0001).	(E,	F)	Serum	
collected	at	end-point	was	analysed	by	ELISA	for	CCL17	and	CCL22.	Two-tailed	
Student’s	t	test,	*	p=0.05,	n=5	for	samples	from	control	treated	(C)	mice,	n=4	for	
samples	from	Affi-5	treated	(T)	mice.	
	 	
	 39	
Figure	3	
Effects	of	anti-CCR4	on	the	RENCA	tumor	associated	macrophages.	Balb/c	mice	were	
injected	with	RENCA-luc	cells	and	treated	with	Affi-5	(T)	or	isotype	control	(C).	Mice	
were	sacrificed	17	days	after	surgery	and	tumors	were	dissociated	and	characterised	by	
flow	cytometry.	(A)	Tumor	infiltrating	macrophages	(gated	as	CD45+	CD11b+	F4/80+)	
per	mg	of	tumor	for	five	independent	experiments	are	shown.	There	was	no	significant	
difference	between	Affi-5-treated	(T)	and	isotype-treated	(C)	tumors	(n=15	and	14,	
respectively).	(B,	C)	Geometric	mean	of	fluorescence	intensity	for	MHCII	and	MR	
staining	on	macrophages	for	five	independent	experiments,	and	staining	for	isotype-
treated	and	Affi-503-treated	dissociated	tumors	for	one	representative	experiment.	
Two-tailed	Student’s	t	test,	p=0.0008	and	p=0.0085,	respectively.	n=19	for	C,	n=17	for	T	
(D)	RNA	was	extracted	from	macrophages	(CD45+	CD11b+	F4/80+)	sorted	by	flow	
cytometry	from	dissociated	tumors.	The	ratio	between	arginase	and	NOS2	expression	
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was	determined	by	real	time	PCR	in	two	independent	experiments	pooled	together	
(Mann-Whitney	U	test,	p=0.035),	with	n=6	for	C,	and	n=7	for	T.	(E)	Cells	were	
dissociated	at	endpoint	from	dissected	tumors	from	Balb/c	mice	treated	with	Affi-5	(T)	
or	isotype	control	(C)	and	plated	overnight	in	the	presence	of	brefeldin	A.	The	fold	
change	in	the	number	of	macrophages	(CD45+	CD11b+	F4/80+)	positive	for	intracellular	
TNFα	is	shown	from	two	pooled	experiments	(Mann-Whitney	U	test,	p=0.002,	n=11	and	
15).	
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Figure	4	
Involvement	of	T	cells	in	the	actions	of	the	anti-CCR4	antibody.	Balb/c	mice	were	
injected	with	RENCA-luc	cells	and	treated	with	Affi-5	(T)	or	isotype	control	(C).	Mice	
were	sacrificed	17	days	after	surgery	and	tumors	were	dissociated	and	characterised	by	
flow	cytometry.	(A,	B)	Number	of	CD45+CD3+	(A),	CD4+	FoxP3+	(Tregs),	CD4+	FoxP3-	
(CD4eff)	and	CD8+	cells/mg	of	tumor	(B)	in	tumors	from	isotype-treated	(C)	or	Affi-5-
treated	(T)	mice	for	four	experiments	pooled	together	(two-tailed	Student’s	t	test,	(A)	
p=0.003	and	(B)	p=0.01,	p=0.02	and	p=0.01	respectively,	with	n=15	for	C,	and	14	for	T).	
(C)	Ratio	between	CD3+,	CD4+,	FoxP3-	or	CD3+,	CD8+	and	CD3+,	CD4+,	FoxP3+	(Treg)	
lymphocytes	in	isotype-treated	and	Affi-5-treated	mice	for	four	experiments	(D)	Two	
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control-treated	(control)	and	two	Affi-5	treated	(treated)	tumors	from	Balb/c	mice	were	
lysed	and	an	amount	equivalent	to	200	µg	tumor	lysate	was	incubated	on	Proteome	
Profiler	Mouse	Cytokine	Array	Panel	A	membranes.	Average	signal	for	each	cytokine	
was	normalised	to	signal	from	control-treated	tumors.	Fold	change	compared	to	
control,	grouped	for	Th1	cytokines	and	Th2	cytokines,	is	shown	(two-tailed	
Student’s	t	test,	p=	0.0173).	(E,	F)	CD3	cells	were	isolated	at	endpoint	from	dissected	
tumors	from	Balb/c	mice	treated	with	Affi-5	(T)	or	isotype	control	(C).	Lymphocytes	
were	stimulated	with	PMA	and	ionomycin	for	4	hours	in	the	presence	of	brefeldin	A	and	
stained	for	intracellular	IFNγ.	The	percentage	of	IFNγ	positive	CD4+	cells	(E)	or	CD8+	cells	
(F)	is	represented.	Two	independent	experiments	pooled	together	are	shown	(two-
tailed	Student’s	t	test,	p=0.028	for	IFNγ	positive	CD4	cells,	n=5	for	C,	n=6	for	T).	(G)	
Percentage	of	CD8	cells	positive	for	granzyme	B	are	represented,	from	four	independent	
experiments.	
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Figure	5	
Other	effects	of	anti-CCR4	antibody	in	the	RENCA	tumor	model.	Balb/c	mice	were	
injected	with	RENCA-luc	cells	and	treated	with	Affi-5	(T)	or	isotype	control	(C).	Mice	
were	sacrificed	17	days	after	surgery	and	tumors	or	spleens	were	dissociated	and	
characterised	by	flow	cytometry.	(A)	Percentage	of	NK	cells	(CD45+	CD3-	DX5+)	among	
the	CD45+	population	in	tumors,	two-tailed	Student’s	t	test,	p=0.0064,	four	
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independent	experiments	pooled	together	(n=12	for	C,	n=15	for	T).	(B)	The	number	of	
NK	cells/mg	of	tumor	was	also	significantly	higher	with	treatment	(two-tailed	
Student’s	t	test,	p=0.032,	n=12	for	C,	n=15	for	T).	(C)	Percentage	of	MDSCs	(CD45+	
CD11+	Gr1+)	among	the	CD45+	infiltrate	for	tumors	from	control	and	treated	animals.	
Two	populations	of	MDSCs	(Gr1high	and	Gr1int)	were	identified	and	analysed	separately.	
Two-tailed	Student’s	t	test,	p=0.0021	and	p=0.0065	for	Gr1high	and	Gr1int	respectively,	
two	experiments	pooled	together,	n=7	for	C	and	n=6	for	T.	(D)	The	fold	change	of	the	
number	of	MDSCs/mg	of	tumor	was	also	significantly	lower	in	the	tumors	from	treated	
animals	(four	experiments,	two-tailed	Student’s	t	test,	p=0.017,	n=12	for	C,	n=11	for	T).	
(E)	Percentage	of	MDSCs	(CD45+	CD11b+	Gr1+)	among	the	CD45+	infiltrate	for	spleens	
from	control	and	treated	animals.	Two	populations	of	MDSCs	(Gr1high	Ly6Cint	and	Ly6Chigh	
Gr1int)	were	identified	and	analysed	separately.	Two-tailed	Student’s	t	test,	p=0.075	for	
Gr1high,	p=0.018	for	Ly6Chigh,	n=3.	(F)	Naive	CD3	isolated	from	spleen	of	healthy	mice	
(5x104/well)	were	pre-labelled	with	CFSE	and	activated	with	anti-CD3	and	anti-CD28-
coated	beads	at	a	ratio	1:2	beads:CD3	cells	in	the	presence	of	freshly	isolated	MDSCs	
from	tumors.	Cells	were	co-cultured	for	3	days,	and	CD4+	and	CD8+	T	cell	proliferation	
was	measured	by	CFSE	dye	dilution	from	two	independent	experiments,	each	pooling	
MDSCs	from	two-three	tumors.	Proliferation	was	inhibited	significantly	(one-way	
ANOVA,	p=0.0012	for	CD4,	p=0.0058	for	CD8,	at	the	MDSCs:T	cells	ratios	of	10:1,	1:1,	
1:2).	
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Figure	6	
Effects	of	anti-CCR4	on	the	RENCA	tumors	require	CD4	cells.	(A,	B,	C,	D)	Balb/c	nu/nu	
mice	were	injected	with	1x105	RENCA-luc	cells	and	treated	with	Affi-5	(T)	or	isotype	
control	(C)	10	mg/kg	twice	weekly	starting	48h	after	surgery.	Mice	were	sacrificed	at	17	
days	after	surgery	and	tumor	weight	was	determined	(n=9	C,	n=8	T,	non	significant).	
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Geometric	mean	of	fluorescence	intensity	for	MHCII	(B)	and	MR	(C)	staining	on	
macrophages	(CD45+,	CD11b+	F4/80+),	for	isotype-treated	and	Affi-503-treated	
dissociated	tumors,	n=4.	(D)	Percentage	of	NK	cells	(CD45+	CD3-	DX5+)	among	the	
CD45+	population,	n=4.	(E,	F,	G,	H)	Balb/c	mice	were	injected	with	1x105	RENCA-luc	cells	
and	treated	with	Affi-5	(T)	or	isotype	control	(C)	10	mg/kg	twice-weekly	starting	48h	
after	surgery.	Treatment	with	anti-MHCII	or	the	relevant	isotype	control	(10	mg/kg)	was	
started	one	day	prior	surgery	and	continued	with	three	doses	per	week.	Mice	were	
sacrificed	at	17	days	after	surgery	and	tumor	weight	was	determined	(n=6	for	each	
group)	and	tumors	were	dissociated	and	characterised	by	flow	cytometry.	(E).	Blocking	
of	MHCII	has	a	significant	effect	on	tumor	weight	(two-way	ANOVA,	p=0.049).	
Bonferroni	post	test	showed	significant	difference	(p<0.05)	between	the	weight	of	Affi-5	
treated	tumors	in	the	presence	or	absence	of	anti-MHCII.	(F,	G)	Geometric	mean	of	
fluorescence	intensity	for	MHCII	(F)	and	MR	(G)	staining	on	macrophages	(CD45+,	
CD11b+	F4/80+).	There	is	significant	difference	between	MHCII	and	MR	expression	of	
macrophages	from	Affi-5	treated	tumors	in	the	presence	or	absence	of	anti-MHCII	(two-
tailed	Student’s	t	test,	p<0.05	and	p<0.001,	respectively,	with	n=3-4	for	each	group)	(H)	
Percentage	of	NK	cells	(CD45+	CD3-	DX5+)	among	the	CD45+	population.	There	is	
significant	difference	(two-tailed	Student’s	t	test,	p<0.001)	between	the	percentage	of	
NK	cells	from	Affi-5	treated	tumors	in	the	presence	or	absence	of	anti-MHCII.	
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Figure	7	
CCL17	can	inhibit	Th1	responses	in	vitro.	(A,	B)	CD4+	cells	were	isolated	from	spleens	of	
healthy	mice	and	stimulated	with	IL-2	and	IL-12	in	the	presence	of	ant-CD3	and	anti-
CD28	coated	beads.	CCL17,	CCL22,	Affi-5	(10	µg/ml)	or	isotype	control	were	added	after	
an	overnight	incubation,	and	after	three	days	cells	were	stimulated	with	Cell	stimulation	
cocktail,	harvested	and	stained	for	intracellular	IFNγ,	and	analysed	by	flow	cytometry.	
Seven	and	three	independent	experiments	are	shown	for	CCL17	and	CCL22,	respectively	
(A),	together	with	representative	plots	of	one	experiment.	Four	independent	
experiments	are	shown	in	(B),	with	representative	plots	for	one	experiment.	
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Figure	8	
Effects	of	anti-CCR4	antibody	is	not	dependent	on	malignant	cell	expression	of	CCR4.	(A)	
Balb/c	mice	were	injected	with	1x105	RENCA-luc	cells	and	treated	with	defucosylated	
Affi-5	(T	(D)),	fucosylated	Affi-5	(T	(F)),	or	defucosylated	isotype	control	(C)	at	10	mg/kg	
twice	weekly	starting	48h	after	surgery.	Mice	were	sacrificed	17	days	after	surgery	and	
tumor	weight	was	analysed	(n=7	(C),	n=8	T	(D),	n=7	T(F)).	Two-tailed	Student’s	t	test,	**	
p<0.01,	*	p<0.05.	(B)	RENCA-luc	cells	were	infected	with	lentivirus	encoding	for	non-
silencing	shRNA,	or	anti-CCR4	shRNA.	Silencing	of	the	infected	cells	lines	was	verified	at	
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Figure 8
** **
	 50	
the	RNA	level	by	RT-PCR.	(C)	Balb/c	mice	were	injected	with	1x105	RENCA-luc	cells	
infected	with	a	non-silencing	lentivirus,	or	CCR4	shRNA	(shCCR4),	and	treated	twice	
weekly	with	Affi-5	at	10	mg/kg	(T)	or	isotype	control	(C),	starting	48h	after	surgery,	n=6	
for	each	group.	Mice	were	sacrificed	17	days	after	surgery	and	tumor	weight	was	
recorded.	Affi-5	treatment	had	an	effect	(two-way	ANOVA,	p=	0.0036),	and	CCR4	
silencing	did	not	interact	significantly	with	the	Affi-5	treatment	(p=0.64).	
	
	
	
	
